[caption id="attachment_71328" align="aligncenter" width="500"] Freepik image[/caption]
As individuals move through different stages of life, the level of support they require can shift along the way. From occasional assistance with daily tasks to full-time care, having access to flexible and tailored support ensures that people maintain independence, dignity, and comfort in their own homes. Understanding how care needs evolve can help families make informed decisions and feel confident that their loved ones are receiving the right level of support at the right time.
Freepik image[/caption]
As individuals move through different stages of life, the level of support they require can shift along the way. From occasional assistance with daily tasks to full-time care, having access to flexible and tailored support ensures that people maintain independence, dignity, and comfort in their own homes. Understanding how care needs evolve can help families make informed decisions and feel confident that their loved ones are receiving the right level of support at the right time.
Dr. Serena Guo[/caption]
Serena Jingchuan Guo, MD PhD
Assistant Professor
Department of Pharmaceutical Outcomes and Policy
University of Florida College of Pharmacy
[caption id="attachment_71231" align="alignleft" width="125"]
Dr. Hao Dai[/caption]
Hao Dai, PhD
Postdoctoral Fellow
Department of Biostatistics & Health Data Science
Indiana University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Obesity and type 2 diabetes are both known to increase the risk of several cancers. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become very popular for both glycemic control and weight loss, but their long-term effects on cancer risk are still unclear. Using a large real-world dataset, we emulated a target trial comparing more than 43,000 GLP-1RA users to matched non-users.
We found that GLP-1RA use was associated with a significantly lower overall cancer risk.
Dr. Del Pozo Cruz[/caption]
MedicalResearch.com Interview with:
Borja del Pozo Cruz, PhD
Department of Sport Sciences
Faculty of Medicine, Health, and Sport Sciences
Universidad Europea de Madrid
MedicalResearch.com: What is the background for this study?
Response: We now have consistent evidence that taking around 7,000 to 10,000 steps per day is associated with substantially lower risks of death and cardiovascular disease. However, much less is known about how those steps are accumulated throughout the day. This question is particularly relevant for people who are mostly inactive, as their steps are often of lower intensity and accumulated in short, fragmented bouts. Understanding whether different step accumulation patterns have distinct health effects in this group is essential to refine physical activity recommendations and make them more inclusive.
Shemyia Smith[/caption]
Shemyia Smith, MBS
Department of Medical Education
Geisinger College of Health Sciences
Scranton, PA 18509
MedicalResearch.com: What is the background for this study?
Response: Over the past several years, legal marijuana (also known as cannabis) use has substantially increased in many states and countries. Alongside this, more patients visit the emergency room and specialist with severe recurring nausea, vomiting, and abdominal pain. Often, this may be misdiagnosed since these symptoms are now known as Cannabinoid Hyperemesis Syndrome (CHS). Although CHS is now widely known, there is still a lot of uncertainty among clinicians about how to diagnose it confidently and manage it effectively.
Dr. Massimiliano[/caption]
MedicalResearch.com Interview with:
Massimiliano Orri, PhD
Assistant Professor in the Department of Psychiatry
McGill University
Principal Investigator at the Douglas Research Centre
within the McGill Group for Suicide Studies.
MedicalResearch.com: What is the background for this study? What types of medical conditions were associated with the early cannabis use?
Response: We already know that cannabis use can be linked to both mental and physical health problems. But what about problems severe enough to require medical attention? In this study, we wanted to see whether young adults who had used cannabis during their teenage years were more likely to seek medical care for mental or physical health issues. Using medical service data allows us to look at more serious cases - those that required professional attention and were diagnosed by healthcare providers. It also helps us understand the broader impact of early cannabis use on the healthcare system
Dr. Dehghani[/caption]
MedicalResearch.com Interview with:
Ali Dehghani, DO
Department of Medicine
University Hospitals Cleveland Medical Center / Case Western Reserve University
Presenting Author, IDWeek 2025
MedicalResearch.com: What is the background for this study?
Response: Shingles (herpes zoster) is caused by reactivation of the varicella-zoster virus, which can inflame blood vessels and the nervous system. Evidence over the past decade has linked shingles to higher risks of heart attack, stroke, and dementia—but it was unclear whether the shingles vaccine might lessen those long-term effects.
[caption id="attachment_71061" align="aligncenter" width="500"]
Clubfoot
Clubfoot
Dr. Jiyoung Ahn[/caption]
MedicalResearch.com Interview with:
Jiyoung Ahn, PhD
Dr. King[/caption]
Brett King, MD, PHD
Dr. King was named an American Academy of Dermatology (AAD) “Patient Care Hero”
for his work treating patients with severe alopecia areata
Dermatology Physicians of Connecticut
Fairfield, Connecticut
MedicalResearch.com: What is the background for this study? Would you briefly explain the condition of Alopecia Areata?
Response: Alopecia Areata (AA), an autoimmune form of hair loss, is common and its treatment has been revolutionized in the past ~3 years with approvals of 3 JAK inhibitors, bariticinib, ritlecitinib and deuruxolitinib. Prior to these approvals, off label treatments included the JAK inhibitors tofacitinib and ruxolitinib.
Prof. Lemesle[/caption]
Gilles Lemesle, M.D., Ph.D
Lille University Hospital, Lille, France
Dr. Casale[/caption]
Thomas B. Casale, M.D.
Professor of Medicine and Pediatrics
Chief of Clinical and Translational Research
Division of Allergy and Immunology
USF Health Morsani College of Medicine
University of South Florida
Tampa, Florida
MedicalResearch.com: What is the background for this study?
Response: The data leading to FDA approval of neffy came from extensive pharmacokinetic and pharmacodynamic studies. As with previous epinephrine delivery devices, the FDA asked for data showing that after delivery of neffy the epinephrine blood levels and expected changes in pulse and blood pressure were similar to those achieved with injectable formulations of epinephrine. neffy performed as expected with blood levels of epinephrine bracketed by those achieved with EpiPen and a needle and syringe along with increases in pulse and blood pressure compatible with the epinephrine levels measured.
Additionally, clinicians are interested in whether neffy would perform similarly in real clinical situations. The data from the neffy experience program provides real-world assurance that neffy can effectively treat acute allergic reactions. Given the large number of patients and the similar findings to those achieved with injectable epinephrine in previous studies, the data should provide assurance that neffy can be an effective substitute for injectable epinephrine in patients that desire a needle-free option.